| Literature DB >> 19732583 |
Paula Gish1, Andrew D Mosholder, Melissa Truffa, Rosemary Johann-Liang.
Abstract
We reviewed Food and Drug Administration postmarketing reports of central nervous system (CNS) anticholinergic effects in association with oxybutynin. Taking domestic usage by age group into account, there is a disproportionately higher number of CNS adverse event cases reported in pediatric patients as compared with adult patients. CNS stimulation was prominent in the pediatric cases.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19732583 DOI： 10.1016/j.jpeds.2009.01.074
Source DB: PubMed Journal: J Pediatr ISSN： 0022-3476 Impact factor: 4.406